According to the ETF Finder at ETF Channel, BMRN makes up 4.39% of the Biotech ETF (BBH) which is up by about 2.5% on the day Wednesday.
In afternoon trading Wednesday, BMRN was up about 2.1% on the day.
There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.